Buch, Englisch, 221 Seiten, Format (B × H): 157 mm x 235 mm, Gewicht: 542 g
Buch, Englisch, 221 Seiten, Format (B × H): 157 mm x 235 mm, Gewicht: 542 g
Reihe: Cancer Drug Discovery and Development
ISBN: 978-1-58829-258-2
Verlag: Humana Press
Zielgruppe
Professional/practitioner
Autoren/Hrsg.
Fachgebiete
Weitere Infos & Material
I. Introduction and Perspective.- 1 Antisense Methodology: An Assessment After 25 Years.- 2 Nucleic Acid Therapeutics: An Introduction.- II. Basic Methodology.- 3 Targeted Genome Modification Via Triple Helix Formation.- 4 Therapeutic Applications of Ribozymes.- 5 Use of Catalytic DNA in Target Validation and Therapeutics.- 6 Targeted Destruction of Small, Stable RNAs: Principles Applicable to Antisense Therapies.- 7 Mechanism of Action of Antisense RNA in Eukaryotic Cells.- III. Delivery.- 8 The Transport of Oligonucleotides Into Cells.- 9 Peptide-Mediated Delivery of Antisense Oligonucleotides and Related Material.- 10 Molecular Vectors for Gene Delivery to Cancer Cells.- IV. Targeting.- 11 Considerations on the Design of Antisense Oligonucleotides.- 12 Identification of Hybridization Accessible Sequence in Messenger RNA.- V. Clinical Targets.- 13 Nucleic Acids As Gene Targeting Therapeutics.- 14 LY900003 (Isis 3521) and G3139 (Genasense; Oblimersen): Phosphorothioate Antisense Oligonucleotides With Pleiotropic Mechanisms of Action.- 15 Antisense Protein Kinase A-RI? Restores Normal Signal Transduction Signatures to Inhibit Tumor Growth.